GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid

negativecamlipixantNegative

AI Analysis

Summary

GSK discontinues camlipixant's late-stage chronic cough (RCC) programme while continuing development in two IBS indications, potentially impacting its $2 billion acquisition of Bellus Health.

Outcome Details

GSK discontinues camlipixant's late-stage RCC programme; continues development in two forms of IBS

Importance:6/10

Sentiment:

-0.70

program discontinuationclinical developmentM&A impactchronic coughIBS

Related Companies

$GSK

Read the original article

Published by Clinical Trials Arena on July 17, 2026 1:49 PM

Read Original